Oxford, UK (10th December, 2013) – BD Diagnostics, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, today introduced two new erythrocyte sedimentation rate (ESR) instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.
Erythrocyte sedimentation is a commonly used hematology test to measure inflammation and the presence and severity of disease. “Improved automation and efficiency are key to carrying out analytical tests in a busy laboratory. More and more tests are being conducted each year and reduced healthcare spending puts pressure on laboratory resources,” comments Stephen Church, European Medical Affairs, BD Diagnostics -Preanalytical Systems.
Manual ESR testing has the potential for errors during the analytical process. The new BD Sedi-20 and BD Sedi-40 combined with BD Seditainer™ tube technology, standardise analysis to improve accuracy. The BD Sedi-40 has an integrated barcode reader and tube mixer. The barcode reader ensures fast, accurate entry of sample identification information. Sample misidentification is one of the many errors which can occur during the preanalytical phase2. The integrated mixer ensures consistent and
standardised mixing of the sample, which is critical in order to obtain an accurate result. Moving from an open manual process to an automated closed process will improve healthcare worker safety by reducing the risk of exposure to blood-borne pathogens.
With an analysis time of just 30 minutes, a 50% reduction in time to result is achieved compared to the gold standard of one hour with Westergren1. BD Sedi-20 can perform 20 tests an hour and the BD Sedi-40 can perform 40 tests an hour. The BD Sedi-40 can be connected to a laboratory information system to enable automatic uploading of results.
BD Sedi-20 and Sedi-40 are being made available in Europe. For more information, contact your local BD representative – or go to: http://www.bd.com/europe/
1. Lippi G, Guidi GC, Risk management in the preanalytical phase of laboratory testing,Clin Chem Lab Med. 2007;45(6):720-7.
2. BD White paper VS9114, an evaluation of erythrocyte sedimentation rate determination using BD Sedi-20 and BD Sedi-40 in comparison to the Westergren method, 2013.
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com
Product Enquiries: Heather Williams, + 44 (0) 7557 001205, Heather_williams@europe.bd.com
Press Enquiries: Laura Blott, + 44 (0) 207 402 0510, laura@lindsellmarketing.com
Help employers find you! Check out all the jobs and post your resume.
